The 20-minute multiplex test delivers eight results covering bacterial vaginosis, Candida species, and trichomoniasis from clinician- or self-collected swabs.
The US Food and Drug Administration (FDA) has granted Dual 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver to bioMérieux for its BIOFIRE SPOTFIRE Vaginitis Panel.
The automated, multiplex polymerase chain reaction (PCR) test runs on the BIOFIRE SPOTFIRE System and is designed to detect the most common causes of vaginitis in about 20 minutes directly at the point of care. The CLIA waiver allows the diagnostic tool to be operated by non-laboratory healthcare personnel.
“Today, there is a clear and persistent gap in vaginitis diagnostics—between the need for accurate, comprehensive testing and the reality of delayed or incomplete results in clinical practice. With the FDA clearance of the BIOFIRE SPOTFIRE Vaginitis Panel, bioMérieux is addressing this gap by bringing fast, syndromic molecular testing directly to the point-of-care setting, enabling healthcare practitioners to move from uncertainty to actionable answers within a single patient visit. This is not just an incremental improvement, it’s a strategic step toward closing a long-standing diagnostics gap in women’s health, fundamentally improving both clinical decision-making and the patient experience,” says Jennifer Zinn, executive vice president of clinical operations at bioMérieux, in a release.
Rapid Multiplex Results During Patient Visits
Vaginitis represents a widespread clinical condition encompassing bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis, often stemming from infection or an altered vaginal microbiome. Traditional diagnostic approaches frequently rely on subjective or low-sensitivity methodologies, leading to misdiagnosis or incomplete evaluation. According to bioMérieux, only about half of women diagnosed with vaginitis via non-molecular testing receive appropriate therapy.
The BIOFIRE SPOTFIRE Vaginitis Panel generates eight results from a single swab, assessing bacterial vaginosis, yeast, and parasite targets. The panel can be utilized with both clinician-collected and patient self-collected vaginal swabs, enabling clinicians to make targeted management decisions within the duration of a standard clinical consultation.
“Not only are the symptoms of vaginitis disruptive and painful, but the underlying condition is also associated with other health conditions, including pelvic inflammatory disease, cervical cancer, adverse birth outcomes, and secondary infections. bioMérieux is proud to bring a better diagnostic solution to patients, which can guide healthcare practitioners in prescribing targeted treatment to more quickly alleviate symptoms and potentially reduce the risk of other negative health consequences,” says Dr Charles K Cooper, executive vice president and chief medical officer at bioMérieux, in a release.
For bacterial vaginosis, the test uses an algorithm that evaluates the relative abundance of multiple organisms to report a binary result. Evaluated bacteria include Fannyhessea (Atopobium) vaginae, Bacterial Vaginosis-Associated Bacterium 2, Lactobacillus crispatus, Lactobacillus gasseri/paragasseri, Lactobacillus jensenii/mulieris, and Sneathia sanguinegens/vaginalis (amnii). The panel also detects six yeast species (Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, and Candida dubliniensis) as well as the parasite Trichomonas vaginalis.
The vaginitis assay broadens bioMérieux’s point-of-care menu on the BIOFIRE SPOTFIRE System, joining existing panels cleared for respiratory tract and sore throat infections. The platform features a compact, modular footprint designed for deployment across diverse care settings, such as outpatient clinics, urgent care centers, and obstetrician/gynecologist (OB/GYN) practices.
Commercial distribution of the BIOFIRE SPOTFIRE Vaginitis Panel is scheduled to begin in the US in early 2027, followed by an extended rollout worldwide.
